• HyperScript III RT SuperMix: High-Fidelity cDNA Synthesis fo

  2026-07-16

  HyperScript III RT SuperMix delivers high-yield, accurate cDNA synthesis for gene expression analysis by qPCR. Its integrated gDNA wiper mix ensures precise removal of genomic DNA, supporting robust profiling from low-abundance and high-GC RNA. This product, developed by APExBIO, is optimized for sensitive and reproducible qRT-PCR workflows.

• Radicicol: Hsp90 Inhibitor Protocols for Apoptosis & Inflamm

  2026-07-16

  Radicicol enables precise modulation of cell fate and inflammation in advanced research, serving as a potent Hsp90 inhibitor with unique workflow flexibility. Explore optimized protocols, troubleshooting strategies, and the latest cross-domain insights to maximize experimental reliability and translational relevance.

• Alosetron as a Precision Tool for 5-HT3 Signaling and Epithe

  2026-07-15

  Explore how Alosetron enables advanced studies of 5-HT3 receptor signaling and intestinal epithelial polarity. This article provides a uniquely integrative analysis, bridging serotonin pharmacology with recent mechanistic insights into stem cell fate determination.

• Redefining Cell Death Analysis: Strategic Advances with Anne

  2026-07-15

  This thought-leadership article bridges mechanistic insight and translational strategy for apoptosis and necrosis detection, spotlighting the APExBIO Annexin V-FITC/7-AAD Apoptosis Kit. By contextualizing the evolving demands of cell viability and cytotoxicity assays with emerging evidence on protein bioactivity and industrial processes, we equip translational researchers with actionable guidance. The piece synthesizes recent advances in rapid microwave heating for protein preservation with best practices in apoptosis workflows, offering a nuanced perspective that transcends typical product pages.

• DFCP1 Regulates ATGL-Driven Lipid Droplet Lipolysis in Starv

  2026-07-14

  This study identifies DFCP1 as a critical, nutrient-sensitive regulator of lipid droplet catabolism through direct modulation of ATGL activity during starvation. The findings clarify how DFCP1 localization and interaction with ATGL influence lipid mobilization, revealing new targets for metabolic disease research.

• Aβ42 Peptide: Mechanistic Leverage for Translational AD Rese

  2026-07-14

  This article unpacks the mechanistic and translational landscape of Amyloid β-Peptide (1-42), equipping researchers with evidence-based insights and strategic guidance for neurotoxicity and microglial phagocytosis assays. By synthesizing foundational literature, advanced workflow recommendations, and the unique attributes of APExBIO’s high-purity Aβ42 peptide, we chart a course for high-impact Alzheimer’s disease model innovation.

• Unlocking TUDCA’s Power: Rethinking ER Stress in Metabolic D

  2026-07-13

  This thought-leadership article reframes Tauroursodeoxycholic Acid (TUDCA) as a strategic reagent for translational researchers tackling the complex nexus of ER stress, autophagy, and metabolic liver disease. Integrating mechanistic insight and practical protocol guidance, it bridges foundational research with actionable recommendations—highlighting the translational stakes emerging from recent discoveries on the galectin-1–FIP200 axis in NAFLD.

• Auranofin: Precision Thioredoxin Reductase Inhibitor for Red

  2026-07-13

  Auranofin is a potent thioredoxin reductase inhibitor with sub-micromolar activity in cancer and antimicrobial research. It induces apoptosis via caspase activation and enhances tumor radiosensitivity. This article details verifiable, protocol-ready facts and clarifies its mechanistic and practical scope.

• Bufuralol Hydrochloride in Translational β-Adrenergic Resear

  2026-07-12

  Explore how Bufuralol hydrochloride, a non-selective β-adrenergic receptor antagonist, is redefining cardiovascular pharmacology research. This article uniquely connects mechanistic insights with next-generation human organoid models, providing a practical roadmap for advanced β-adrenergic modulation studies.

• Metabolic Intervention Enhances Ferroptosis and Cuproptosis

  2026-07-10

  This study introduces a nanosystem-based metabolic intervention that synchronously increases tumor cell susceptibility to ferroptosis and cuproptosis by targeting glycolysis and NAD+ metabolism. The strategy not only amplifies regulated cell death but also strengthens anti-tumor immune responses, laying a technical foundation for combined metabolic and cell death pathway therapies.

• DGLA-Induced Ferroptosis via ACSL4 in Acute Myeloid Leukemia

  2026-07-09

  The referenced study demonstrates that exogenous dihomo-γ-linolenic acid (DGLA) triggers ferroptosis in acute myeloid leukemia (AML) cells by reprogramming lipid metabolism through ACSL4. This finding advances the understanding of non-apoptotic cell death modalities in AML and highlights potential new therapeutic strategies for overcoming chemoresistance.

• WM-8014: Advancing KAT6A Inhibition for Translational Epigen

  2026-07-09

  This thought-leadership article explores the paradigm-shifting role of WM-8014, a potent and selective KAT6A inhibitor, in the evolving landscape of epigenetic cancer research. Blending mechanistic insight, recent experimental advances, and translational strategy, it offers practical guidance for researchers seeking to harness oncogene-induced senescence and cell cycle arrest with precision. The discussion bridges newly uncovered epigenetic dependencies in SCC resistance, practical protocol parameters, and the competitive landscape, while offering a visionary outlook on the future of selective histone acetyltransferase inhibition.

• Distinct Apoptotic Pathways in BMECs Triggered by Candida kr

  2026-07-08

  This study reveals that the yeast and hypha forms of Candida krusei induce apoptosis in bovine mammary epithelial cells (BMECs) via separate signaling mechanisms—mitochondrial and death receptor pathways, respectively. The findings clarify the molecular underpinnings of mycotic mastitis and highlight JNK/ERK and TLR2/ERK signaling as key mediators, informing targeted research and potential intervention strategies.

• Dual-Action Inhibitors Accelerate p38α MAPK Dephosphorylatio

  2026-07-08

  The reference study reveals that certain p38α kinase inhibitors not only block catalytic activity but also enhance dephosphorylation by phosphatase WIP1, offering a dual-action mechanism for greater specificity. This mechanistic insight informs the design of more selective inhibitors for inflammatory disease research and expands strategies for modulating kinase signaling.

• CHIR 99021 Trihydrochloride: GSK-3 Inhibitor for Organoid Pr

  2026-07-07

  CHIR 99021 trihydrochloride empowers researchers to achieve unprecedented control over stem cell self-renewal and differentiation in organoid and metabolic disease models. Its potency and selectivity as a GSK-3 inhibitor, validated by recent breakthroughs, make it a cornerstone for scalable, high-diversity, and physiologically relevant human tissue modeling.

449 records 11/30 page Previous Next First page 上5页 1112131415 下5页 Last page